公开(公告)号：US09932386B2

公开(公告)日：2018-04-03

申请号：US14112620

申请日：2012-04-19

Applicant: Asya Grinberg ,  Roselyne Castonguay ,  Eric Werner ,  Ravindra Kumar

Inventor： Asya Grinberg ,  Roselyne Castonguay ,  Eric Werner ,  Ravindra Kumar

IPC: C07K14/705 ,  A61K38/00

CPC classification number: C07K14/70596 ,  A61K38/00 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/24 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/41 ,  C07K2319/50 ,  C07K2319/705

Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.

公开(公告)号：US08765663B2

公开(公告)日：2014-07-01

申请号：US13404593

申请日：2012-02-24

Applicant: Jasbir Seehra ,  Ravindra Kumar ,  Jennifer Lachey ,  Alan Koncarevic

Inventor： Jasbir Seehra ,  Ravindra Kumar ,  Jennifer Lachey ,  Alan Koncarevic

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K31/00 ,  A61K31/7088 ,  A61K38/179 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30

Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.

Abstract translation: 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。

公开(公告)号：US08722615B2

公开(公告)日：2014-05-13

申请号：US12959220

申请日：2010-12-02

Applicant: Jasbir Seehra ,  John Knopf ,  Ravindra Kumar

Inventor： Jasbir Seehra ,  John Knopf ,  Ravindra Kumar

IPC: A61K38/00

CPC classification number: C07K14/7151 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.

公开(公告)号：US08353972B2

公开(公告)日：2013-01-15

申请号：US12025528

申请日：2008-02-04

Applicant: Rakesh Sarin ,  Ravindra Kumar ,  Suresh Kumar Puri ,  Anurag Ateet Gupta ,  Ravinder Kumar Malhotra ,  Satish Makhija

Inventor： Rakesh Sarin ,  Ravindra Kumar ,  Suresh Kumar Puri ,  Anurag Ateet Gupta ,  Ravinder Kumar Malhotra ,  Satish Makhija

IPC: C10L1/19 ,  C10L1/08

CPC classification number: C07C29/34 ,  C07C51/16 ,  C07C67/08 ,  C07C69/24 ,  C10L1/026 ,  C10L1/19 ,  C10L10/08 ,  C10L10/12 ,  C10L10/14 ,  Y02E50/13 ,  Y02T50/678 ,  C07C31/125 ,  C07C53/128

Abstract: Disclosed is a novel synthetic fuel as alternative to diesel, wherein said synthetic fuel comprises branched esters and wherein the fuel having improved fuel properties such as zero aromatic, zero olefin, zero sulphur, low pour, high cetane diesel fuel with improved lubricity and oxidative stability. Further, the present invention provides a method of preparation of said esters.

Abstract translation: 公开了一种新型合成燃料作为柴油的替代物，其中所述合成燃料包括支链酯，并且其中燃料具有改进的燃料性质，例如零芳香族，零烯烃，零硫，低倾倒，具有改善的润滑性和氧化稳定性的高十六烷值柴油 。 此外，本发明提供了所述酯的制备方法。

公开(公告)号：US08346952B2

公开(公告)日：2013-01-01

申请号：US11963646

申请日：2007-12-21

Applicant: Kartik Kumar ,  James Hartwell Holl, II ,  Anshu Surana ,  Ravindra Kumar

Inventor： Kartik Kumar ,  James Hartwell Holl, II ,  Anshu Surana ,  Ravindra Kumar

IPC: G06F15/16

CPC classification number: H04L63/20 ,  G06F21/604 ,  H04L63/105

Abstract: An embodiment of a network manager permits a resource group administrator (with resource group level permissions but without global permissions) to add a global object to his/her resource group as a managed object, without requiring the administrator to have a global permission, as discussed further below. An embodiment of the network manager permits a resource group administrator to also edit the configuration settings that are attached to his/her resource group without requiring the administrator to have a global permission.

Abstract translation: 网络管理员的一个实施例允许资源组管理员（具有资源组级别权限，但没有全局权限）将全局对象添加到他/她的资源组作为被管理对象，而不要求管理员具有全局权限，如所讨论的 进一步在下面。 网络管理员的一个实施例允许资源组管理员还编辑附加到他/她的资源组的配置设置，而不需要管理员具有全局权限。

公开(公告)号：US08293881B2

公开(公告)日：2012-10-23

申请号：US12796307

申请日：2010-06-08

Applicant: Jasbir Seehra ,  Ravindra Kumar

Inventor： Jasbir Seehra ,  Ravindra Kumar

IPC: C07H21/04 ,  C12N15/09 ,  C12N5/02

CPC classification number: C12N9/12 ,  A61K38/00 ,  C07K14/475 ,  C07K14/71 ,  C07K2319/30 ,  C12N2510/02 ,  C12Y207/1103

Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.

Abstract translation: 在某些方面，本发明提供了用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪，棕色脂肪和/或神经元组织的生长并用于治疗代谢性疾病如糖尿病和肥胖的组合物和方法 ，以及与任何前述组织相关的疾病。

公开(公告)号：US20120148588A1

公开(公告)日：2012-06-14

申请号：US13403657

申请日：2012-02-23

Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

IPC: A61K39/395 ,  A61P21/00 ,  A61P3/00

CPC classification number: C07K16/40 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/1796 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P21/00 ,  C07K14/71 ,  C07K2319/30 ,  C12N5/0602

Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

Abstract translation: 在某些方面，本发明提供通过施用ActRIIB信号传导途径的拮抗剂来增加产热脂肪细胞（例如，棕色脂肪细胞或其他表达UCP-1的脂肪细胞）的组合物和方法。 这些拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗肌生成抑制素抗体，抗GDF3抗体，抗-Nodal，抗激活素和抗GDF11抗体。 可以通过引起生热脂肪细胞的增加来治疗各种代谢和其它疾病。

公开(公告)号：US20110171218A1

公开(公告)日：2011-07-14

申请号：US12959220

申请日：2010-12-02

Applicant: Jasbir Seehra ,  John Knopf ,  Ravindra Kumar

Inventor： Jasbir Seehra ,  John Knopf ,  Ravindra Kumar

IPC: A61K39/395 ,  C07H21/00 ,  C12P21/00 ,  C12N5/10 ,  C07K19/00 ,  A61P29/00 ,  A61P37/06 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P33/00 ,  A61P25/28 ,  A61P25/16 ,  C12N1/00

CPC classification number: C07K14/7151 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.

Abstract translation: 本文提供了具有增加的血清半衰期的糖型变异Fc融合蛋白。 还提供了通过引入一个或多个非内源糖基化位点来增加Fc融合蛋白的血清半衰期的方法。

公开(公告)号：USD619351S1

公开(公告)日：2010-07-13

申请号：US29346429

申请日：2009-10-30

Applicant: Vandana Verma ,  Ravindra Kumar

Designer： Vandana Verma ,  Ravindra Kumar

公开(公告)号：US20100160225A1

公开(公告)日：2010-06-24

申请号：US12586207

申请日：2009-09-18

Applicant: John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

Inventor： John Knopf ,  Jasbir Seehra ,  Ravindra Kumar

IPC: A61K38/16 ,  C07K14/435 ,  C07K16/00 ,  C12N15/12 ,  C12N5/16 ,  C12N5/22 ,  C12P21/00 ,  A61P21/00 ,  A61P3/04 ,  A61P25/00 ,  A61P29/00 ,  A61P9/00 ,  A61P9/12 ,  A61P11/00

CPC classification number: C07K14/47 ,  A61K38/00 ,  C07K14/495

Abstract: The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.

Abstract translation: 本公开涉及Lefty衍生物和Lef多肽作为某些配体如Nodal，GDF-8（Myostatin）和GDF-11功能的拮抗剂的用途。 这些衍生物可以与其它功能异源蛋白如IgG，特别是IgG的Fc部分融合。 根据该公开内容，Lefty多肽可用于治疗各种疾病，包括例如神经元疾病，肌肉和骨骼状况以及代谢紊乱。